This study is for patients with advanced non-small cell lung cancer (NSCLC) that has a specific gene change called MET exon 14 skipping. It tests a drug called tepotinib alone or with another drug called ramucirumab. Tepotinib blocks a protein that makes cancer cells grow, while ramucirumab stops blood vessels that feed tumors. This trial checks if using these drugs together can help stop the cancer from spreading.

• The study lasts several years with follow-up visits every 12 weeks initially.
• Patients undergo regular scans and blood tests during the study.
• Participants must not have had certain other cancer treatments recently and must meet specific health criteria.

To join, patients need to have a MET exon 14 skipping mutation confirmed by a lab test. They need regular scans and medical check-ups. The drugs are given in cycles, and patients are monitored for side effects. Participants must not have other certain gene changes in their cancer and should not be pregnant or breastfeeding. This study could help understand how well these drugs work together, offering new hope for lung cancer patients.